SKYE
Skye Bioscience, Inc.1.1900
+0.1100+10.2%
Dec 16, 4:00:00 PM EST
Earnings Call Transcripts
This Quarter (Q1 '26)
No earnings call transcript available yet
Last Quarter (Q4 '25)
No earnings call transcript available
Key Stats
Market Cap
38.15MP/E (TTM)
-Basic EPS (TTM)
-1.30Dividend Yield
0%Recent Filings
8-K
Nasdaq bid price deficiency
Skye Bioscience received a Nasdaq deficiency notice on March 17, 2026, for its common stock trading below $1.00 for 30 consecutive business days, violating Rule 5450(a)(1). Shares continue trading under SKYE with 180 days until September 14, 2026, to regain compliance via $1.00 closes over 10 business days or a reverse stock split. No assurance of success. Delisting looms if unmet.
8-K
Q4 results, nimacimab advances
Skye Bioscience reported Q4 and full-year 2025 results, posting a $55.9M net loss amid ramped R&D to $42.4M for nimacimab manufacturing, with cash at $25.7M funding operations through Q4 2026. CBeyond combo with semaglutide delivered 22.3% weight loss at 52 weeks, no plateau, and superior post-treatment regain. Cash burn accelerates. Expansion study tests higher IV doses; topline due Q4 2026.
10-K
FY2025 10-K: Halozyme license deal
Skye Bioscience filed its 10-K for FY2025 ended December 31, 2025, with no revenue or profitability disclosed as a clinical-stage biotech. No quarterly breakdowns, GAAP totals, or Q4 metrics appear in the filing. Key development: signed non-exclusive license and collaboration with Halozyme effective December 18, 2025, for PH20 Drug to enable subcutaneous delivery of Skye's CB-1 targeting biologic, granting preclinical and commercial rights worldwide. No financials, debt, cash flow, capex, or guidance provided. Clinical trials pending. No buybacks or dividends. Market value of non-affiliate equity hit $129.5M as of June 30, 2025. Clinical trial delays could stall momentum.
8-K
CFO departs; CEO adds accounting duties
Skye Bioscience's CFO Kaitlyn Arsenault steps down February 20, 2026, to pursue other opportunities, securing $450,000 severance, $45,000 bonus, $30,000 legal fees, and 12 months COBRA coverage. CEO Punit Dhillon assumes principal accounting officer role same day, terms unchanged. She advises six months while equity vests. No disagreements on finances.
8-K
22.3% weight loss at 52 weeks
Skye Bioscience disclosed interim Phase 2a extension data on February 2, 2026, showing nimacimab plus semaglutide delivered 22.3% mean weight loss at 52 weeks in 7 participants, outpacing placebo plus semaglutide's 19.7%—no plateau observed. Combo cut 13-week off-therapy regain to 17.8% versus 37.3%. Safety held firm. Full data due Q3 2026; cash lasts to Q4. Nimacimab boosts durability.
ALT
Altimmune, Inc.
5.03-0.25
ENVB
Enveric Biosciences, Inc.
5.24-0.12
IMA
ImageneBio, Inc.
6.25+0.08
KALA
KALA BIO, Inc.
0.56-0.05
KLRS
Kalaris Therapeutics, Inc.
8.66+0.16
MTSR
Metsera, Inc.
70.50-0.25
OKYO
OKYO Pharma Limited
1.88-0.01
SABS
SAB Biotherapeutics, Inc.
3.99-0.01
SGMT
Sagimet Biosciences Inc. - Seri
6.05+0.02
SPRC
SciSparc Ltd.
1.61-0.03